Board-ready drug discovery diligence for go, no-go, and portfolio prioritization decisions.

If you are about to commit a nine-figure budget to a biopharmaceutical program, you should have a diligence-grade memo that integrates human evidence, mechanism, clinical history, and competitive risk into a single recommendation.